Heron Therapeutics | HRTX - Ebit

金融业

USD

USD 255.88M

现金及等价物

USD 43.07M

USD 11.12M

USD 238.07M

USD 96.1M

USD 149.65M

股息收益率

0

USD 38K

USD -3.88M

126

EPS每股收益

USD -0.02

股本和储备

USD 13.28M

USD 29.47M

债务利息支出

USD 600K

USD 433K

USD 140.64M

USD 115M

USD -2.95M

USD 40.55M

USD 38K

普通股股本

USD 188.31M

USD -2.95M

USD 40.59M

销售和管理费用

USD 23.74M

USD 54.57M

贸易债权人

USD 8.99M

应收帐款人

USD 89.59M

	Ebit	更改		日
ALKERMES	USD -10.95M		100.03M	2025-12
Alnylam Pharmaceuticals	USD 29.4M		59.36M	2025-12
Amarin	USD -2.26M		564K	2025-12
ANI Pharmaceuticals	USD 29.13M		6.3M	2025-12
Anika Therapeutics	USD 646K		3.88M	2025-12
Arrowhead Research	USD 40.81M		17.01M	2025-12
Eisai	JPY 20.03B		6.36B	2025-12
Esperion Therapeutics	USD 85.23M		95.19M	2025-12
GlaxoSmithKline	GBP 1.44B		1.35B	2025-12
Heron Therapeutics	USD 38K		3.83M	2025-12
Insmed	USD -249.71M		11.64M	2025-12
Ligand Pharmaceuticals	USD 158.89M		115.32M	2025-09
Merck	USD 6.24B		1.32B	2025-12
Nektar Therapeutics	USD -34.34M		3.68M	2024-09
Neurocrine Biosciences	USD 227.9M		11.4M	2025-12
Omeros	USD -48.15M		7.25M	2023-09
Pacira	USD 3.19M		9.96M	2025-12
Regeneron Pharmaceuticals	USD 898.6M		211.3M	2025-12
Roche Holding	CHF 9.56B		2.1B	2025-12
Surmodics	USD -322K		2.13M	2023-12
Ultragenyx Pharmaceutical	USD -114M		56.89M	2025-12
Veracyte	USD 24.63M		1.52M	2025-12
Vertex Pharmaceuticals	USD 1.26B		24.5M	2025-12